CDK4 and neoplasm: In this study, we show that reactivation of wildtype p53 using NVP-CGM097 is an effective inhibitor of tumour growth in multiple models of endocrine-naïve, endocrine-resistant and CDK4/6 inhibitor-resistant ER-positive breast cancer in vitro and in vivo.